Yahoo · Sep 18, 2026
3 Dividend Stocks to Buy and Hold for 10 Years
They have a knack for increasing their dividends even when facing challenges.
AB
NYSE · ABT
Abbott Laboratories
Healthcare · Medical - Devices
$102.61
Up+$0.32 (+0.31%)
Updated Sep 20, 2026, 9:29 AM
SID Score
6.1/10
Composite research score
Smart Money
44/100
Neutral
- Market cap
- 202.45B
- P/E ratio
- 31.15
- Dividend yield
- 2.30%
- 52-week range
- $81.97 – $129.64
- Volume
- 27.08M
- Avg. volume
- 8.88M
Price performance
ABT price history
1M range · 19 trading sessions · Daily adjusted prices
ABT closed at $102.61 after 19 trading sessions, down 12.05% for the selected period.
- Last close
- $102.61
- Period change
- -12.05%
- Period low
- $101.95
- Period high
- $116.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $101.83 | $103.19 | $101.50 | $102.61 | 27.08M |
| Sep 17, 2026 | $102.15 | $102.995 | $100.33 | $102.23 | 8.43M |
| Sep 16, 2026 | $101.89 | $103.30 | $101.50 | $102.36 | 5.23M |
| Sep 15, 2026 | $102.98 | $103.06 | $101.47 | $102.03 | 7.42M |
| Sep 14, 2026 | $103.56 | $104.44 | $102.57 | $103.09 | 7.79M |
| Sep 11, 2026 | $104.15 | $104.18 | $101.49 | $101.95 | 8.4M |
| Sep 10, 2026 | $105.18 | $105.19 | $103.18 | $103.36 | 7.85M |
| Sep 9, 2026 | $105.69 | $106.8599 | $104.78 | $105.23 | 6.47M |
| Sep 8, 2026 | $108.36 | $108.39 | $105.24 | $105.52 | 11.4M |
| Sep 4, 2026 | $108.105 | $110.01 | $107.36 | $108.33 | 7.03M |
| Sep 3, 2026 | $110.91 | $112.00 | $108.04 | $108.79 | 5.3M |
| Sep 2, 2026 | $109.32 | $112.20 | $109.00 | $110.47 | 8.46M |
| Sep 1, 2026 | $112.25 | $113.91 | $108.68 | $108.93 | 7.23M |
| Aug 31, 2026 | $111.54 | $111.64 | $109.54 | $110.36 | 10.69M |
| Aug 28, 2026 | $111.60 | $112.75 | $111.11 | $112.47 | 7.55M |
| Aug 27, 2026 | $112.75 | $113.45 | $111.29 | $111.59 | 8.36M |
| Aug 26, 2026 | $115.40 | $116.715 | $114.005 | $114.10 | 6.96M |
| Aug 25, 2026 | $115.83 | $116.61 | $115.035 | $116.13 | 7.5M |
| Aug 24, 2026 | $116.28 | $117.34 | $115.82 | $116.67 | 5.92M |
Latest ABT news
The latest Smart Investors Daily articles mentioning ABT.
Stock researchCompany · Overview
ABT research
Overview
Company profile and research snapshot.
Company profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $151.40
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | TD Cowen | Buy | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 17, 2026 | TD Cowen | Buy | — |
News briefing
Generated Sep 19, 2026, 9:00 PM
Why Is ABT Moving Slightly Higher Today?
Abbott Laboratories edged up 0.31% today as investors digest the company's continued dividend strength and positioning in high-growth medical device markets. The modest gains reflect a steady-as-she-goes sentiment around this defensive healthcare dividend aristocrat, with recent headlines underscoring its reliability rather than catalyzing significant momentum.
Bottom line: Abbott's modest daily gain reflects its stable positioning as a premier dividend stock with secular growth drivers in healthcare markets, though the stock lacks explosive near-term catalysts. Investors should view ABT as a core holding for long-term wealth building through dividends and moderate capital appreciation, while monitoring competitive dynamics in key device markets and potential margin pressures.
Yahoo · Sep 18, 2026
Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi
Yahoo · Sep 18, 2026
Why Wall Street Is Becoming Even More Bullish About This Dividend King
Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.
Yahoo · Sep 17, 2026
Abbott declares 411th consecutive quarterly dividend
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
AI research layers
Interpretive context generated from the platform’s current data sources.
Abbott Laboratories Stock Performance
Abbott Laboratories shares trade at $102.55, sitting below both the 50-day moving average of $106.02 and the 200-day moving average of $102.90, per SID market data. The stock has declined 10.33% over the past month, though it has gained 16.06% over the trailing three-month period. On a one-year basis, ABT has dropped 18.21%, underperforming the broader healthcare sector. The 14-day relative strength index registers at 20.4, placing the stock firmly in oversold territory and indicating significant recent selling pressure. Abbott carries a beta of 0.751, reflecting lower volatility relative to the overall market. Average daily trading volume stands at approximately 8.88 million shares, according to Massive/Polygon data. The company's market capitalization is approximately $202.5 billion, maintaining its position as one of the largest diversified healthcare companies by market value.
Abbott Laboratories Valuation Analysis
Abbott Laboratories currently trades at a price-to-earnings ratio of 31.15, per SID market data, reflecting a premium valuation relative to broader market averages. The company's PEG ratio stands at -0.58, according to SEC filings, which signals a disconnect between the current earnings multiple and forward growth expectations. Abbott's price-to-book ratio is 3.90, indicating investors are paying nearly four times book value per share. In the healthcare sector, such multiples are common among diversified medical device and diagnostics companies with established brand portfolios. The stock offers a dividend yield of 2.06%, providing income-oriented investors with a yield that exceeds the S&P 500 average. Abbott's valuation metrics suggest the market continues to assign a premium for the company's diversified revenue streams spanning medical devices, diagnostics, nutrition, and established pharmaceuticals, even as shares have experienced notable downward pressure over the trailing twelve months.
Smart Money Activity for ABT
Abbott Laboratories registers a composite smart money score of 44 out of 100, carrying a neutral signal per SID market data. Institutional positioning scores a perfect 25 out of 25, indicating strong conviction among large asset managers, according to 13F institutional filings. In contrast, insider activity scores 9.7 out of 25, with 14 insider transactions recorded over the past 90 days per SEC Form 4 filings. These transactions are evenly split between seven purchases and seven sales, suggesting no clear directional conviction from corporate insiders. Dark pool activity registers at 8.5 out of 25, indicating relatively limited off-exchange institutional accumulation in recent weeks. Congressional trading activity is minimal at 0.8 out of 25, showing negligible involvement from elected officials' disclosed portfolios. The divergence between maximum institutional conviction and moderate insider activity creates a mixed picture, with large fund managers maintaining robust positions while company executives demonstrate balanced trading behavior around current price levels.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution in its most recent reported quarters. In the quarter reported on April 16, 2026, the company posted earnings per share of $1.15, matching the consensus estimate of $1.14 and delivering a positive surprise of $0.01, per company earnings reports. The subsequent quarter reported on July 16 showed further improvement, with actual EPS of $1.31 exceeding the analyst estimate of $1.28 by $0.03. Looking ahead, analysts project EPS of $1.15 for the period with results expected around April 15, and $1.42 for the quarter anticipated on October 14, 2026, according to analyst estimates. The sequential step-up from $1.15 to $1.31 in reported results reflects a 13.9% quarter-over-quarter improvement. Abbott's pattern of modest upside earnings surprises suggests disciplined guidance practices, with management consistently delivering results at or slightly above Wall Street expectations.
Wall Street Analyst Ratings for ABT
Wall Street analysts maintain a broadly constructive stance on Abbott Laboratories, per SID consensus data. TD Cowen has been the most active coverage firm, reiterating its Buy rating on three separate occasions — on July 17, August 25, and September 8, 2026 — according to Wall Street analyst reports. UBS similarly maintained its Buy rating on July 28, reinforcing institutional conviction following the company's earnings report. The most notable recent action came from Wolfe Research on August 13, which upgraded ABT to Outperform from Peer Perform, representing the sole rating change among recent coverage updates. All five of the most recent analyst actions carry either Buy or Outperform designations, with no Hold or Sell ratings observed in the current coverage window. This unanimous bullish positioning stands in contrast to the stock's 18.21% one-year decline and deeply oversold RSI reading of 20.4, suggesting analysts view current levels as disconnected from fundamental value based on their forward estimates.
